Sowell Financial Services LLC Acquires 19,278 Shares of Pfizer Inc. $PFE

Key Points

• Sowell Financial Services LLC increased its stake in Pfizer Inc. by 10.8%, owning 197,334 shares valued at approximately $4.78 million.
• Pfizer's most recent earnings report showed an EPS of $0.78, surpassing expectations, with quarterly revenue of $14.65 billion, marking a 10.3% year-over-year increase.
• The company announced a quarterly dividend of $0.43 per share, representing a 7.2% dividend yield and a payout ratio of 91.49%.

Sowell Financial Services LLC grew its holdings in Pfizer Inc. (NYSE:PFE - Free Report) by 10.8% during the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 197,334 shares of the biopharmaceutical company's stock after acquiring an additional 19,278 shares during the period. Sowell Financial Services LLC's holdings in Pfizer were worth $4,783,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in PFE. Gould Capital LLC increased its stake in Pfizer by 97.2% during the 4th quarter. Gould Capital LLC now owns 1,000 shares of the biopharmaceutical company's stock worth $27,000 after buying an additional 493 shares during the period. GKV Capital Management Co. Inc. purchased a new stake in Pfizer during the 1st quarter worth $27,000. North Capital Inc. acquired a new position in Pfizer during the 1st quarter worth $28,000. Bayforest Capital Ltd acquired a new position in Pfizer during the 1st quarter worth $28,000. Finally, Bernard Wealth Management Corp. acquired a new position in Pfizer during the 4th quarter worth $30,000. Hedge funds and other institutional investors own 68.36% of the company's stock.

Wall Street Analyst Weigh In

PFE has been the subject of several recent analyst reports. Wall Street Zen raised shares of Pfizer from a "hold" rating to a "buy" rating in a report on Saturday. Bank of America lifted their price objective on shares of Pfizer from $27.00 to $28.00 and gave the company a "neutral" rating in a research report on Wednesday, August 6th. Morgan Stanley lifted their price objective on shares of Pfizer from $32.00 to $33.00 and gave the company an "equal weight" rating in a research report on Wednesday, August 6th. Berenberg Bank cut their price objective on shares of Pfizer from $28.00 to $25.00 and set a "hold" rating on the stock in a research report on Thursday, May 29th. Finally, Citigroup lifted their price objective on shares of Pfizer from $25.00 to $26.00 and gave the company a "neutral" rating in a research report on Wednesday, August 6th. Two analysts have rated the stock with a Strong Buy rating, four have given a Buy rating, eleven have assigned a Hold rating and one has assigned a Sell rating to the company's stock. According to MarketBeat, the stock currently has a consensus rating of "Hold" and a consensus price target of $28.12.

Pfizer Price Performance

Shares of NYSE PFE traded up $0.02 during midday trading on Monday, reaching $24.05. The company's stock had a trading volume of 67,725,099 shares, compared to its average volume of 45,384,523. The company has a current ratio of 1.16, a quick ratio of 0.85 and a debt-to-equity ratio of 0.65. The company has a 50 day moving average price of $24.63 and a 200 day moving average price of $24.20. Pfizer Inc. has a one year low of $20.92 and a one year high of $30.43. The company has a market cap of $136.74 billion, a price-to-earnings ratio of 12.79, a price-to-earnings-growth ratio of 0.78 and a beta of 0.55.

Pfizer (NYSE:PFE - Get Free Report) last released its earnings results on Tuesday, August 5th. The biopharmaceutical company reported $0.78 EPS for the quarter, topping analysts' consensus estimates of $0.58 by $0.20. Pfizer had a net margin of 16.84% and a return on equity of 21.42%. The business had revenue of $14.65 billion for the quarter, compared to the consensus estimate of $13.43 billion. During the same period in the previous year, the firm earned $0.60 EPS. The business's revenue for the quarter was up 10.3% on a year-over-year basis. Pfizer has set its FY 2025 guidance at 2.900-3.100 EPS. On average, equities research analysts expect that Pfizer Inc. will post 2.95 EPS for the current year.

Pfizer Dividend Announcement

The business also recently disclosed a quarterly dividend, which was paid on Tuesday, September 2nd. Investors of record on Friday, July 25th were given a dividend of $0.43 per share. The ex-dividend date of this dividend was Friday, July 25th. This represents a $1.72 dividend on an annualized basis and a yield of 7.2%. Pfizer's payout ratio is presently 91.49%.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.